Judy Olian - United Therapeutics Independent Director
| UTHR Stock | USD 262.40 0.00 0.00% |
Director
Dr. Judy D. Olian, Ph.D. serves as Independent Director of the Company. Dr. Olian has served as President of Quinnipiac University since July 2018. Previously, she served as dean of the UCLA Anderson School of Management and the John E. Anderson Chair in Management from 2006 to 2018. Her research and business expertise centers on aligning organizational strategies and design with human resource systems and incentives, and managing top management teams. She began her UCLA appointment after serving as dean and professor of management at the Smeal College of Business Administration at Pennsylvania State University. Earlier, she served in various faculty and executive roles at the University of Maryland and its Robert H. Smith School of Business since 2015.
| Age | 66 |
| Tenure | 9 years |
| Address | 1000 Spring Street, Silver Spring, MD, United States, 20910 |
| Phone | 301 608 9292 |
| Web | https://www.unither.com |
United Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.1122 % which means that it generated a profit of $0.1122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1827 %, meaning that it created $0.1827 on every $100 dollars invested by stockholders. United Therapeutics' management efficiency ratios could be used to measure how well United Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/04/2024, Return On Tangible Assets is likely to grow to 0.15. Also, Return On Capital Employed is likely to grow to 0.20. At this time, United Therapeutics' Return On Tangible Assets are relatively stable compared to the past year. As of 05/04/2024, Debt To Assets is likely to grow to 0.10, while Other Assets are likely to drop slightly above 284.7 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Stephen Biggar | Kiniksa Pharmaceuticals | 47 | |
| Paul Friedman | Incyte | 75 | |
| Michael Friedman | MannKind Corp | 73 | |
| Alec Machiels | Apellis Pharmaceuticals | 45 | |
| Paul Schimmel | Alnylam Pharmaceuticals | 77 | |
| Charles Rowland | Blueprint Medicines Corp | 59 | |
| Shehnaaz Suliman | Ultragenyx | 46 | |
| David MacCallum | MannKind Corp | 77 | |
| Stephanie OBrien | Apellis Pharmaceuticals | 59 | |
| Hyam Levitsky | Replimune Group | 59 | |
| Rafaele Tordjman | Ascendis Pharma AS | 45 | |
| Christine Mundkur | MannKind Corp | 49 | |
| Lynn Seely | Blueprint Medicines Corp | 59 | |
| Michael Narachi | Ultragenyx | 57 | |
| Michael Mayer | Ascendis Pharma AS | 59 | |
| JeanJacques Bienaime | Incyte | 64 | |
| Thomas Malley | Kiniksa Pharmaceuticals | 49 | |
| Martin Olin | Ascendis Pharma AS | 48 | |
| Mark Goldberg | Blueprint Medicines Corp | 63 | |
| Jonathan Silverstein | Ascendis Pharma AS | 49 | |
| Tracey McCain | Kiniksa Pharmaceuticals | 50 | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.11 |
United Therapeutics Leadership Team
Elected by the shareholders, the United Therapeutics' board of directors comprises two types of representatives: United Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of United. The board's role is to monitor United Therapeutics' management team and ensure that shareholders' interests are well served. United Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, United Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Patusky, Lead Independent Vice Chairman of the Board | ||
| Christopher Causey, Independent Director | ||
| Patrick Poisson, Executive Operations | ||
| Richard Giltner, Independent Director | ||
| Martine Rothblatt, Chairman of the Board, CEO | ||
| Holly Hobson, Associate Resources | ||
| Katherine Klein, Director | ||
| Dewey CFA, Head Relations | ||
| John Ferrari, CFO and Treasurer | ||
| Michael Benkowitz, President COO | ||
| Raymond Dwek, Non-Independent Director | ||
| James Edgemond, CFO and Treasurer | ||
| Paul JD, General VP | ||
| Paul Mahon, Executive Vice President General Counsel, Corporate Secretary | ||
| Raymond Kurzweil, Non-Independent Director | ||
| Leigh Peterson, Senior Development | ||
| Tommy Thompson, Independent Director | ||
| JD MBA, Chairman Founder | ||
| Gil Golden, Senior Officer | ||
| Roger Jeffs, Co-CEO and President and Director | ||
| Kevin Gray, Senior Logistics | ||
| Nilda Mesa, Independent Director | ||
| Judy Olian, Independent Director | ||
| David Zaccardelli, COO, Executive Vice President | ||
| Louis Sullivan, Independent Director |
United Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is United Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.42 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 8.77 B | ||||
| Shares Outstanding | 44.37 M | ||||
| Shares Owned By Insiders | 1.84 % | ||||
| Shares Owned By Institutions | 98.16 % | ||||
| Number Of Shares Shorted | 4.32 M | ||||
| Price To Earning | 23.49 X |
United Therapeutics Investors Sentiment
The influence of United Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in United. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average United Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on United Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards United Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, United Therapeutics' short interest history, or implied volatility extrapolated from United Therapeutics options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in United Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stocks Directory Find actively traded stocks across global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.626 | Earnings Share 19.8 | Revenue Per Share 49.733 | Quarterly Revenue Growth 0.251 | Return On Assets 0.1122 |
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.